These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32715376)

  • 41. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature.
    Islam B; Ahmed M; Islam Z; Begum SM
    Skelet Muscle; 2021 Apr; 11(1):10. PubMed ID: 33883014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 and Dialysis Patients: Unsolved Problems in Early 2021.
    Kliger AS; Silberzweig J
    J Am Soc Nephrol; 2021 May; 32(5):1018-1020. PubMed ID: 33637517
    [No Abstract]   [Full Text] [Related]  

  • 44. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.
    Wang Z; Wang Z
    BMC Infect Dis; 2021 Jan; 21(1):113. PubMed ID: 33494706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports.
    Deveci B; Saba R
    Medicine (Baltimore); 2021 Dec; 100(52):e28470. PubMed ID: 34967391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of high-dose intravenous immunoglobulin in severe and critical COVID-19: A retrospective cohort study.
    Aggarwal R; Dewan A; Pandey A; Trehan N; Majid MA
    Int Immunopharmacol; 2022 May; 106():108615. PubMed ID: 35168081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
    Barrasa H; Rello J; Tejada S; Martín A; Balziskueta G; Vinuesa C; Fernández-Miret B; Villagra A; Vallejo A; San Sebastián A; Cabañes S; Iribarren S; Fonseca F; Maynar J;
    Anaesth Crit Care Pain Med; 2020 Oct; 39(5):553-561. PubMed ID: 32278670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
    Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
    J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments.
    Boban M
    Int J Clin Pract; 2021 Apr; 75(4):e13868. PubMed ID: 33244856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
    Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome.
    Kim-Hellmuth S; Hermann M; Eilenberger J; Ley-Zaporozhan J; Fischer M; Hauck F; Klein C; Haas N; Kappler M; Huebner J; Jakob A; von Both U
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):543-546. PubMed ID: 33188394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuous venous hemodialysis integrated to the ECMO circuit in critically ill patient with COVID-19, a case report in Morocco.
    Mounir A; Lamghari S; Raja A; Allali K; Chebbar S; Buri B; Mahdar Y; Kettani CE; Ramdani B; Ettaoumi Y; Benouna G; Barrou L
    Pan Afr Med J; 2020; 35(Suppl 2):141. PubMed ID: 33193956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
    Ali S; Shalim E; Farhan F; Anjum F; Ali A; Uddin SM; Shahab F; Haider M; Ahmed I; Ali MR; Khan S; Rao S; Guriro K; Elahi S; Ali M; Mushtaq T; Sayeed MA; Muhaymin SM; Luxmi S; Saifullah ; Qureshi S
    Trials; 2022 Nov; 23(1):932. PubMed ID: 36348476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxidative stress in patients with coronavirus disease and end-stage renal disease: a pilot study.
    Beck NS; Seo Y; Park T; Jun SS; Im JI; Hong SY
    BMC Nephrol; 2024 May; 25(1):155. PubMed ID: 38702607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.